US FDA adds label warning to J&J’s and Legend Biotech’s cancer therapy

Investing.comMonday, October 13, 2025 at 1:42:24 AM
US FDA adds label warning to J&J’s and Legend Biotech’s cancer therapy
The US FDA has issued a label warning for the cancer therapy developed by Johnson & Johnson and Legend Biotech, highlighting potential risks associated with the treatment. This development is significant as it raises concerns about patient safety and could impact the therapy's usage in clinical settings. The warning may lead to increased scrutiny from healthcare providers and patients alike, emphasizing the importance of thorough communication regarding treatment options.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
US FDA adds boxed warning to J&J, Legend Biotech’s cancer therapy
NegativeFinancial Markets
The US FDA has issued a boxed warning for the cancer therapy developed by Johnson & Johnson and Legend Biotech, highlighting serious risks associated with its use. This warning is significant as it alerts healthcare providers and patients to potential severe side effects, which could impact treatment decisions and patient safety. The move underscores the importance of monitoring drug safety and ensuring that patients are fully informed about the risks involved in their treatment.
FDA approves Teva's UZEDY for bipolar I disorder maintenance
PositiveFinancial Markets
The FDA has approved Teva's UZEDY for the maintenance treatment of bipolar I disorder, marking a significant advancement in mental health care. This approval is crucial as it provides patients with a new option to manage their condition effectively, potentially improving their quality of life. With bipolar disorder affecting millions, UZEDY's introduction could lead to better treatment outcomes and support for those struggling with this challenging disorder.
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says
PositiveFinancial Markets
Johnson & Johnson is reportedly in discussions to acquire Protagonist Therapeutics, a move that could significantly enhance its portfolio in the pharmaceutical sector. This acquisition is important as it reflects J&J's strategy to bolster its research and development capabilities, particularly in innovative therapies. If successful, this deal could lead to new treatments and advancements in healthcare, benefiting patients and investors alike.
Johnson & Johnson in Talks to Buy Protagonist Therapeutics
PositiveFinancial Markets
Johnson & Johnson is in discussions to acquire Protagonist Therapeutics, a move that could significantly enhance their collaboration on a treatment for ulcerative colitis. This acquisition is important as it not only strengthens their existing partnership but also highlights the growing focus on innovative therapies in the healthcare sector.
Latest from Financial Markets
Wingtech stock plunges after Dutch government intervenes in chip unit
NegativeFinancial Markets
Wingtech's stock has taken a significant hit following intervention by the Dutch government in its chip unit. This move raises concerns about the company's future and its ability to navigate regulatory challenges, which could impact investor confidence and market stability. The intervention highlights the increasing scrutiny on tech companies and their operations, making it a critical moment for Wingtech and its stakeholders.
FTSE 100 Set to Rebound, Pound Holds Above $1.33
PositiveFinancial Markets
The FTSE 100 is poised for a rebound as the pound remains strong above $1.33 against the dollar. This stability in the currency is encouraging for investors, signaling confidence in the UK economy. A rising FTSE 100 could lead to increased investment and economic growth, making this a significant development for both local and international markets.
India watchdog asks Air India to inspect emergency power system on some 787 jets
NeutralFinancial Markets
India's aviation watchdog has requested Air India to conduct inspections on the emergency power systems of certain 787 jets. This move is significant as it ensures the safety and reliability of the aircraft, which is crucial for maintaining passenger confidence and operational integrity. Regular checks like these are essential in the aviation industry to prevent potential issues and uphold safety standards.
China’s stocks sink on fresh US trade war salvo
NegativeFinancial Markets
China's stock market has taken a significant hit following new trade tensions with the United States. This downturn is concerning as it reflects the ongoing economic struggles and uncertainties that could impact global markets. Investors are worried about the potential for escalating tariffs and trade barriers, which could further strain the already fragile economic relationship between the two countries.
Sampo Oyj repurchases 307,924 own shares as part of buyback program
PositiveFinancial Markets
Sampo Oyj has successfully repurchased 307,924 of its own shares as part of its ongoing buyback program. This move is significant as it reflects the company's commitment to enhancing shareholder value and demonstrates confidence in its financial health. By reducing the number of shares in circulation, Sampo Oyj aims to increase earnings per share, which can positively influence stock prices and investor sentiment.
China Comfortable Working with Trump: Eurasia's Meale
PositiveFinancial Markets
David Meale from the Eurasia Group has shared insights on the positive outlook among Chinese business leaders regarding their ability to collaborate with President Trump. Despite ongoing trade tensions, there is a sense of optimism in Beijing, with both parties believing that a trade deal is still within reach. This perspective is crucial as it highlights the potential for improved relations and economic cooperation between the U.S. and China, which could have significant implications for global markets.